SCHEMBL7250091

SCHEMBL7250091

Cc1nc(CS)cs1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10031019 0.80 PKM (0.51)
SCHEMBL91500 0.78
SCHEMBL12919512 0.77 SMN1; SMN2 (0.44)
SCHEMBL208648 0.76
SCHEMBL131562 0.76
SCHEMBL8371077 0.76
SCHEMBL16848089 0.76
SCHEMBL7250089 0.76
SCHEMBL914923 0.76
SCHEMBL507355 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6562844-B2 Attaching an olefin to a solid support; oxidizing the olefin to provide an epoxide functionality; opening the epoxide with an amine to form an amino alcohol; cyclizing the amino alcohol using a phosgene equivalent PHARMACIA & UPJOHN COMPANY 2003-05-13 US claimed
WO-2015002150-A1 NOVEL COMPOUND, ORGANIC CATION TRANSPORTER 3 DETECTION AGENT, AND ORGANIC CATION TRANSPORTER 3 ACTIVITY INHIBITOR 株式会社新日本科学 (JP) 2015-01-08 WO disclosed
US-20070281937-A1 Ion Channel Modulators SCION PHARMACEUTICALS, INC. 2007-12-06 US disclosed
US-20070203194-A1 Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders SCION PHARMACEUTICALS, INC. (US) 2007-08-30 US disclosed
US-20070203194-A1 Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders SCION PHARMACEUTICALS, INC. (US) 2007-08-30 US disclosed
WO-2005087750-A1 ION CHANNEL MODULATORS WYETH (US) 2005-09-22 WO disclosed
US-6156761-A Substituted tetralone derivatives for enhancing cognition MERCK SHARPE & DOHME LIMITED (GB) 2000-12-05 US disclosed
EP-0182301-B1 3-SUBSTITUTED CARBACEPHEM AND CEPHEM COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS KYOWA HAKKO KOGYO CO., LTD. (JP) 1991-06-12 EP disclosed
US-4760060-A 3-heteroaralkylthio carbacephem compounds and antibacterial pharmaceutical composition KYOWA HAKKO KOGYO CO., LTD. (JP) 1988-07-26 US disclosed
US-4746736-A THIENAMYCINS, BACTERICIDES BRISTOL-MYERS COMPANY (US) 1988-05-24 US disclosed
US-4732977-A BACTERICIDES BRISTOL MYERS COMPANY (US) 1988-03-22 US disclosed
US-4644061-A Carbapenem antibiotics BRISTOL-MYERS COMPANY (US) 1987-02-17 US disclosed
EP-0182301-A2 3-Substituted carbacephem and cephem compounds and pharmaceutical compositions KYOWA HAKKO KOGYO CO., LTD. (JP) 1986-05-28 EP disclosed